Introduction
============

A common feature of influenza disease is the "clinical iceberg" phenomenon, which states that many mild cases of infection escape clinical detection owing to the lack of severe symptoms presented.[@ref1] This phenomenon is certainly true for interpandemic influenza[@ref2] as well as for the influenza A/H1N1 pandemic in 2009.[@ref3] However, A/H5N1 is an acknowledged exception,[@ref4] whereas the A/H7N7 outbreak in the Netherlands suggested that there was a large submerged portion of the iceberg, but which was not as substantial as that for other interpandemic human strains.[@ref5] [@ref6]

The influenza A/H7N9 virus emerged in early 2013, and people with infections initially confirmed in the laboratory were admitted to hospital with serious illness.[@ref7] [@ref8] Most laboratory confirmed infections have been found in residents of urban areas, who have reported recent exposure to live poultry,[@ref9] [@ref10] and investigations of live poultry markets have identified a high prevalence of influenza A/H7N9 virus in poultry.[@ref11] However, comparison of the incidence of laboratory confirmed cases with patterns in exposure suggests that seriousness of infection may increase with age, and that some mild infections may have gone undetected in younger adults.[@ref12] [@ref13] In addition, a small number of laboratory confirmed cases have been identified through China's national sentinel surveillance system for influenza-like illness.[@ref14]

Here, we describe the clinical characteristics of all patients with A/H7N9 infections as of 27 May 2013, who were identified through routine testing by the sentinel surveillance system for influenza-like illness. These findings could indicate the sizable proportion of people with milder infections and who would otherwise not have been detected, which would be important if present circulating strains of A/H7N9 were to acquire the ability to spread efficiently among humans. Moreover, there is an urgent need to better understand how these patients may present at the clinical interface, and if they represent a separately identifiable group. The objective of our study was to characterise the complete case series of A/H7N9 infections as of 27 May 2013, identified through China's national sentinel surveillance system for influenza-like illness.

Methods
=======

Sources of cases
----------------

All laboratory confirmed A/H7N9 infections are reported to the Chinese Center for Disease Control and Prevention through a national sentinel surveillance system. Case definitions, surveillance for identification of A/H7N9 cases, and laboratory test assays have been described in a previous report.[@ref9] A joint field investigation team---comprising staff of the Centers for Disease Control and Prevention at the local, provincial, and national level---conducted field investigations of the laboratory confirmed cases of A/H7N9 virus infection.

Surveillance of influenza-like illness in China
-----------------------------------------------

Surveillance of influenza-like illness and its associated virology in China is conducted through a national sentinel network across the country. The network consists of outpatient clinics and emergency departments of 554 sentinel hospitals across 31 provinces in mainland China, covering 2.5% of all hospitals in China. Data for cases of influenza-like illness included the total number of outpatient or emergency department visits, and the number of patients fitting the World Health Organization's standard case definition of influenza-like illness (that is, body temperature ≥38°C with either a cough or sore throat in the absence of an alternative diagnosis) is reported on a weekly basis through a centralised online system to the Chinese Center for Disease Control and Prevention.

For each sentinel site, 10-15 nasopharyngeal swabs are collected each week by convenience samples of patients with influenza-like illness who had not taken antiviral drugs and who had fever (\>38°C) for no longer than three days. These swabs undergo routine virological testing and subtyping, and results are reported to the Chinese Center for Disease Control and Prevention within 24 h.[@ref15] Surveillance is conducted throughout the year to systematically collect data all year round with a consistent sampling frame. Outpatient clinics or emergency departments in hospitals represent a typical first step for patients with influenza-like illness in China to present to the healthcare system, owing to the coverage of national health insurance programmes and the lack of standalone primary healthcare clinics in either the public or private sector as an alternative. Although the selection of patients with influenza-like illness for virology testing was not random, there should not have been any incentive for selection according to clinical severity, because results would not have been fed back to doctors for treatment purposes. Therefore, the sentinel surveillance system for influenza-like illness is believed to capture typical patients in the community, and thought to give a representative picture of the disease in China.

By cross-referencing the laboratory confirmed cases of A/H7N9 infection with patients detected by the sentinel surveillance system for influenza-like illness, we could identify all infected patients detected through the surveillance system as of 27 May 2013. We extracted demographic and epidemiological data from public health investigations by the local, provincial, and national level Centers for Disease Control and Prevention; and clinical and laboratory data from chart review.

Results
=======

Among the 130 laboratory confirmed cases of A/H7N9 infection as of 27 May 2013, five patients were first identified through the sentinel surveillance system for influenza-like illness. The earliest laboratory confirmed cases occurred in the Yangtze River Delta, and more recent cases were detected to the north and south. Figure 1[](#fig1){ref-type="fig"} shows the geographical location of 130 confirmed cases, and the five cases detected through sentinel surveillance. Figure 2[](#fig2){ref-type="fig"} shows the timing of illness onset in those five cases compared with the other laboratory confirmed cases in affected provinces.

![**Fig 1** Distribution of laboratory confirmed cases of influenza A/H7N9 virus infection in mainland China, by location, between 19 February and 3 May 2013. Red squares=five cases detected through the sentinel surveillance system; blue circles=all other cases. Provinces are shaded according to population density, and A/H7N9 cases with more recent calendar dates of illness onset are represented by symbols with darker shades](ipde012849.f1_default){#fig1}

![**Fig 2** Distribution of laboratory confirmed cases of influenza A/H7N9 virus infection in mainland China, by time. Number of cases by calendar date of illness onset in Shanghai, Jiangsu, Zhejiang, Fujian, and other provinces](ipde012849.f2_default){#fig2}

Clinical characteristics
------------------------

The five patients identified by the sentinel surveillance system for influenza-like illness (patients 1-5) ranged in age from 2 to 26 years (mean 13 years), of whom four (80%) were male. They lived in urban areas of three different provinces. Date of symptom onset ranged from 17 March to 26 April 2013. Three patients were young children, and four had a confirmed history of exposure to live animals, including chickens. All presented with fever, and most with upper respiratory tract symptoms. Four were captured by the surveillance system within the next day, and one within two days of symptom onset. All five patients had mild to moderate disease and have since recovered. Among them, three (60%) were managed only as outpatients, and the other two (40%) were admitted to hospital and subsequently discharged. One patient had pneumonia without requiring intensive care. All close contacts of these five patients underwent medical surveillance and had remained well. Figure 3[](#fig3){ref-type="fig"} summarises key clinical milestones of each patient, and table 1[](#tbl1){ref-type="table"} shows their epidemiological characteristics.

![**Fig 3** Clinical milestones of patients 1-5 detected through routine sentinel surveillance for influenza-like illness in China. RT-PCR=reverse transcriptase-polymerase chain reaction](ipde012849.f3_default){#fig3}

###### 

 Epidemiological and clinical characteristics of five patients with influenza A/H7N9 identified through routine surveillance for influenza-like illness in China

                                                                       Patient 1                          Patient 2                          Patient 3                          Patient 4                                 Patient 5
  -------------------------------------------------------------------- ---------------------------------- ---------------------------------- ---------------------------------- ----------------------------------------- ----------------------------------
  Age (years)                                                          2                                  4                                  26                                 26                                        9
  Sex                                                                  Male                               Male                               Female                             Male                                      Male
  Location                                                             Shanghai                           Shanghai                           Jiangsu                            Jiangsu                                   Fujian
  Residential setting                                                  Urban                              Urban                              Urban                              Urban                                     Urban
  Underlying medical conditions                                        None                               None                               None                               None                                      None
  Type of exposure                                                     Data unavailable                   Poultry exposure around the home   Exposure to pigeon                 Work place close to live poultry market   Poultry exposure around the home
  No of close contacts traced                                          9                                  18                                 5                                  21                                        Data unavailable
  Date of illness onset                                                17 March 2013                      31 March 2013                      8 April 2013                       8 April 2013                              26 April 2013
  Presenting symptoms                                                  Fever                              Fever, rhinorrhoea                 Fever, myalgia                     Fever, productive cough                   Fever, diarrhoea, malaise
  Pneumonia (as indicated by lung consolidation on chest radiograph)   No                                 No                                 No                                 Yes (left sided)                          No
  Mechanical ventilation                                               No                                 No                                 No                                 No                                        No
  Time from illness onset to clinical milestone                                                                                                                                                                           
   First visit at any medical facility (days)                          1                                  1                                  1                                  1                                         1
   Visit to surveillance sentinel clinic (days)                        1                                  1                                  1                                  2                                         1
   Admission to hospital (days)                                        Never admitted                     3                                  Never admitted                     4                                         Never admitted
   Receiving antiviral treatment (days)                                Not treated with antiviral drugs   3                                  Not treated with antiviral drugs   4                                         Not treated with antiviral drugs
   Recovery or hospital discharge (days)                               5                                  10 (hospital discharge)            4                                  18 (hospital discharge)                   3

Patient 1 was a 2 year old child from Shanghai, patient 3 was a 26 year old woman from Jiangsu, and patient 5 was a 9 year old primary school student from Fujian. Patients 3 and 5 had a history of poultry exposure. They all presented with fever and were seen within one day of symptom onset in a designated site of the sentinel surveillance system for influenza-like illness. Nasopharyngeal swabs were taken, as part of the 10-15 routine samples per week for virological surveillance. Because patients 1, 3, and 5 all had a mild presentation, they were not suspected to have been infected by A/H7N9 and were managed as outpatients without antiviral prescription. All three patients quickly recovered after 3-5 days. Nasopharyngeal swabs collected at the first visit to the ILI sentinel clinics for all three patients were tested positive for A/H7N9 after their full recovery.

Patient 2 was a 4 year old child from Shanghai, who developed a fever of 39°C and mild rhinorrhoea on 31 March 2013, and was seen in a routine sentinel clinic on 1 April, where a nasopharyngeal swab taken. He was admitted to hospital on 3 April when the swab tested positive for A/H7N9, and was started on oseltamivir 45 mg twice daily for five days. His chest radiograph on admission (fig 4[](#fig4){ref-type="fig"}) and other laboratory findings showed no abnormalities (table 2[](#tbl2){ref-type="table"}). He remained clinically stable, and his symptoms quickly resolved. When two consecutive nasopharyngeal samples tested negative on 8 and 9 April, he was discharged on 10 April.

![**Fig 4** Radiological findings of patient 2 with influenza A/H7N9 infection, identified through routine sentinel surveillance for influenza-like illness in China](ipde012849.f4_default){#fig4}

###### 

 Laboratory and treatment characteristics of patients 2 and 4 with influenza A/H7N9 identified through routine surveillance for influenza-like illness in China

                                                                Patient 2 (mild infection)                    Patient 4 (moderate infection)
  ------------------------------------------------------------- --------------------------------------------- --------------------------------------------------------------------------------------------
  Laboratory findings                                                                                         
   White blood cell count (10^9^ cells/L)                       6.2                                           5.9
   Neutrophils (10^9^ cells/L)                                  2.6                                           3.2
   Lymphocytes (10^9^ cells /L)                                 3.0                                           2.4
   Haemoglobin (g/L)                                            114                                           186
   Platelets (10^9^ cells /L)                                   279                                           129
   Alanine transaminase (U/L)\*                                 9                                             63
   Aspartate transaminase (U/L)\*                               24                                            87
   Creatinine (μmol/L)                                          25.0                                          49.9
   Creatine kinase (U/L)\*                                      31.0                                          605.8
   Lactate dehydrogenase (U/L)\*                                223                                           1849
   Potassium (mmol/L)                                           3.7                                           3.6
   Sodium (mmol/L)                                              149                                           133.8
   Glucose (mmol/L)                                             Test not done                                 Test not done
   C reactive protein (nmol/L)                                  8.0                                           Test not done
   Fraction of inspired oxygen (FiO~2~)                         Test not done                                 0.3
   Arterial oxygen partial pressure (PaO~2~; mm Hg)†            Test not done                                 62.0
   Arterial carbon dioxide partial pressure (PaCO~2~, mm Hg)†   Test not done                                 42.0
   PaO~2~:FiO~2~ ratio                                          Test not done                                 206.7
  Treatment                                                                                                   
   Antiviral drugs                                              Oseltamivir (45 mg, twice daily for 5 days)   Oseltamivir (150 mg, twice daily for 4 days; then 75 mg, twice daily for 4 days)
   Steroids                                                     No                                            No
   Antibiotics                                                  No                                            Ceftazidime (1 g, once every 6 h for 3 days); then moxifloxacin (400 mg, daily for 2 days)
   Intravenous immunoglobulin                                   No                                            No

\*1 U/L=0.0167 µkat/L.

†1 mm Hg=0.133 kPa.

Patient 4 was a 26 year old man from Jiangsu who first had fever and a productive cough with yellowish sputum on 8 April. He sought care at a routine sentinel clinic two days later, and was prescribed 1 g ceftazidime every 6 h. He presented again on April 12 with fever of 38.5°C, and was admitted to hospital and started on oseltamivir 75 mg twice daily and moxifloxacin 400 mg once daily. Initial investigation revealed radiological evidence of left sided pneumonia (fig 5[](#fig5){ref-type="fig"}) and mildly elevated concentrations of serum transaminases (table 2). His nasopharygeal swab at the sentinel clinic tested positive for A/H7N9 after his admission. He improved clinically and was discharged on 26 April 2013.

![**Fig 5** Radiological findings of patient 4 with influenza A/H7N9 infection, identified through routine sentinel surveillance for influenza-like illness in China. Chest radiograph on admission shows ground glass opacity at upper and middle lung fields on patient's left side](ipde012849.f5_default){#fig5}

Discussion
==========

Summary and clinical implications of results
--------------------------------------------

The complete case series of A/H7N9 infections detected to date through China's national sentinel surveillance system for influenza-like illness has provided contrasting clinical presentations to the generally more severe presentations of A/H7N9 cases reported so far.[@ref7] [@ref9] The five patients detected by the surveillance system were much younger, on average, than the cohort of people with laboratory confirmed infections (13 years *v* about 60 years). But both groups otherwise shared similar epidemiological characteristics---including exposure history, geographical location, and calendar time of disease onset. However, none of the five patients had any chronic underlying medical conditions, unlike many in the general cohort of confirmed cases.[@ref7] [@ref9] [@ref16] Our report expands on a preliminary assessment of six people with A/H7N9 infections who were identified either through the routine sentinel surveillance system for influenza-like illness or through enhanced surveillance among inpatients with atypical pneumonia, established as part of the response to A/H7N9.[@ref14] [@ref17]

Our findings reinforce the need for vigilance to the diverse presentation that can be associated with A/H7N9 infection. This vigilance is important not only in the interest of direct patient care, but also in terms of public health, because a large proportion of unidentified cases with mild infection in the community may be a source of infection to other susceptible people if A/H7N9 develops the capacity for human to human transmission, thus making an epidemic potentially much more difficult to control.

Strengths and limitations of the study
--------------------------------------

Because five (4%) of the 130 patients with laboratory confirmed infections presented with mild disease and were detected only by the sentinel surveillance system for influenza-like illness, our findings provide indirect evidence of a substantial proportion of mild disease. This proportion would be in keeping with most influenza strains, with the notable exception of A/H5N1, to varying degrees. Systematic seroepidemiology studies will provide definitive evidence in time, by use of a cross-sectional design and by longitudinal paired sampling. In the interim, however, formal techniques for statistical inference can give bounded estimates to inform real time decision making in public health. Additionally, any simple computation of the "confirmed case fatality risk"---that is, dividing the number of deaths by the total number of laboratory confirmed and reported cases---could be complicated by a denominator that is probably much larger (as these results suggest), thus upward biasing the projection of mortality burden in the population.

At the system level, although sentinel surveillance systems for influenza-like illness are primarily designed for informing situational awareness rather than actual case finding in an epidemic setting,[@ref1] our results suggest that large scale surveillance networks in the community can be useful as a population based sampling tool to enhance understanding of the full spectrum of disease, especially in the early phase of an evolving epidemic such as the present one.

Importantly, this report is limited by the lack of associated viral genetic data. Future work should investigate any potential divergence in viral characteristics by phylogenetic and deep sequencing analysis between cases detected by various different routes---that is, routine surveillance for influenza-like illness versus direct clinical presentation otherwise.

### What is already known on this topic

1.  The "clinical iceberg" phenomenon of milder cases that escape detection is a common feature of influenza

2.  Most reports of infection from the novel influenza A/H7N9 virus have so far presented a severe clinical picture

3.  It remains unknown whether the clinical iceberg phenomenon applies to A/H7N9

### What this study adds

1.  Evidence suggests that there is an important proportion of mild disease, and supports the existence of a clinical iceberg phenomenon in influenza A/H7N9 infections

2.  Our findings reinforce the need for vigilance to the diverse presentation that can be associated with influenza A/H7N9 infections
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